Consistently, 2EF showed powerful antitumor activity in multiple Trop-2-expressing preclinical tumor models, among them the SKOv3 ovarian, Colo205, HT29, HCT116 U5.5 colon and DU-145 prostate cancers. Here, TACSTD2 is linked to prostate carcinoma.